시간 외 거래: 1.32

Theratechnologies Inc. (THTX)

Theratechnologies Inc. 주식(THTX)의 최신 뉴스

Theratechnologies Inc. (THTX)

Theratechnologies Inc. 주식(THTX)의 최신 뉴스

Theratechnologies (TSE:TH) Share Price Passes Below 200-Day Moving Average of $2.03 - MarketBeat

Closing Bell: Theratechnologies down on Friday (TH) - The Globe and Mail

Theratechnologies Announces New Board Chair - TipRanks.com - TipRanks

Theratechnologies Elects New Board Chair - TipRanks.com - TipRanks

Theratechnologies Reports on its Annual Meeting of Shareholders - GlobeNewswire

Theratechnologies rend compte de son assemblée annuelle des actionnaires

Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH) - Simply Wall St

Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH) - Simply Wall St

Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel ... - GlobeNewswire

Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?

SGIOY: 3 Biotech Stocks to Buy to Power Through April - StockNews.com

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of ... - GlobeNewswire

Theratechnologies First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Leede still bullish on Theratechnologies following “soft” quarter - Cantech Letter

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 - Yahoo Finance

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ ... - GlobeNewswire

Theratechnologies Strengthens Board with New Appointment - TipRanks.com - TipRanks

Theratechnologies Appoints Elina Tea to its Board of Directors

Theratechnologies Appoints Elina Tea to its Board of Directors - GlobeNewswire

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology ... - Yahoo Finance

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Theratechnologies phases down preclinical oncology research | 2024-03-22 | Investing News - Stockhouse Publishing

Theratechnologies nomme Jordan Zwick à son conseil d’administration

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced ... - GlobeNewswire

CORRECTION - Theratechnologies annonce la démission de l’un de ses administrateurs, M. Alain Trudeau

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau - GlobeNewswire

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

Theratechnologies Faces FDA Setback on Trogarzo - TipRanks.com - TipRanks

Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock

BMRN: Eyeing Growth? Check Out These 3 Biotech Stock Buys - StockNews.com

Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St

Theratechnologies présente ses résultats financiers pour le quatrième trimestre et l’exercice complet 2023 et des prévisions pour 2024

Theratechnologies: Fiscal Q4 Earnings Snapshot - Quartz

Theratechnologies annonce la publication d’un article dans Frontiers in Immunology qui approfondit la compréhension du mécanisme d’action moléculaire du sudocétaxel zendusortide (TH1902)

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update - Yahoo Finance

FDA denies approval for Theratechnologies' tesamorelin F8 - Pharmaceutical Technology

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA - GlobeNewswire

Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application

Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application - GlobeNewswire

THTX과 유사한 종목